NET CLINICAL TRIALS IN CANADA

For an up-to-date listing of all active recruiting NET Clinical Trials please visit: Neuroendocrine Tumour Open Trials – Canada

The following information on active Neuroendocrine clinical trials in Canada was taken from the clinicaltrials.gov website.

Click on each trial to go to more information including protocol, objectives, entry criteria, investigators and locations in Canada.

Status Study Title Intervention Locations
Recruiting 68Ga-DOTA-TATE PET/CT Imaging in NETs
Diagnostic Test: 68Ga-DOTA-TATE
CHUS – Sherbrooke, Quebec, Canada
Recruiting A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours
Drug: [177]Lu-DOTA-TATE
Cross Cancer Institute – Edmonton, Alberta, Canada
Recruiting 68Ga-DOTATATE PET for Management of Neuroendocrine Tumors
Diagnostic Test: 68Ga -DOTATATE PET scans
Princess Margaret Cancer Centre – Toronto, Ontario, Canada
Recruiting DOTATOC PET/CT for Imaging NET Patients
Diagnostic Test: 68Ga-DOTATOC PET/CT
Diagnostic Test: 18F-FDG PET/CT
BC Cancer – Vancouver, British Columbia, Canada
Recruiting Lesion-to-lesion Comparison of 68Ga-HA-DOTATATE, 18F-DOPA, and 18F-FDG PET/CT in the Evaluation of Metastatic Neuroendocrine Tumors
Diagnostic Test: 18F-DOPA with furosemide
University of Alberta Hospital – Edmonton, Alberta, Canada
Recruiting Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors
Drug: F18-FDG
Princess Margaret Cancer Centre – Toronto, Ontario, Canada
Recruiting Personalized PRRT of Neuroendocrine Tumors
Drug: 177Lu-Octreotate
CHU de Québec – Université Laval – Quebec City, Quebec, Canada
Recruiting A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET (SORENTO)

SORENTO PATIENT BROCHURE
Drug: CAM2029
Drug: Octreotide LAR
Drug: Lanreotide ATG
London Health Sciences Centre – London, Ontario
The Ottawa Hospital General Campus – Ottawa, Ontario
Princess Margaret Cancer Centre – Toronto, Ontario
Sunnybrook Health Sciences Centre – Toronto, Ontario
BC Cancer Agency Vancouver Centre – Vancouver, BC
Recruiting A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use
Drug: [68]Ga-HA-DOTATATE
Cross Cancer Institute – Edmonton, Alberta, Canada
Recruiting 68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors
Drug: 68Ga-HA-DOTATATE
University of Alberta – Edmonton, Alberta, Canada
Recruiting Dynamic Whole Body Positron Emission Tomography/Computed Tomography Imaging
Diagnostic Test: 18F-FDG PET/CT
Diagnostic Test: 68Ga-DOTATOC PET/CT
BC Cancer – Vancouver, British Columbia, Canada
Recruiting 18F-DOPA II – PET Imaging Optimization
Drug: 18F-DOPA
Drug: Furosemide Injection
WC Mackenzie Health Science Centre / University of Alberta Hospital – Edmonton, Alberta, Canada
Not yet recruiting 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs
Drug: 177Lu-DOTATOC
BC Cancer – Vancouver, British Columbia, Canada
Recruiting Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
Drug: Lutetium [177Lu] oxodotreotide/dotatate
CHU de Québec – Université Laval – Québec, Canada
Recruiting FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for Treatment of Patients With Select Solid Tumors (FRONTIER)
Drug: [Ga-68]-PNT6555
Drug: [Lu-177]-PNT6555
University Health Network – Princess Margaret Cancer Centre – Toronto, Ontario, Canada
CHUM – Centre hospitalier de l’Université de Montréal – Montréal, Quebec, Canada
Jewish General Hospital – Montréal, Quebec, Canada

Recruiting

Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
Drug: 40 mg or 80 mg Paltusotine
Crinetics Study Site – Toronto, Ontario

Share This Story, Choose Your Platform!